Male Breast Cancer Completed Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00006228Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast CancerTreatment
NCT00024154Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerTreatment
NCT00077376Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast CancerTreatment